Targets › PPIX
2 programs from 2 companies in 3 trials: 1 Phase 3, 1 Phase 1, 1 Phase 4; Oncology; next expected readout Dec 2028.
Open in Phaseline: the race on PPIX, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Roma La Sapienza | Hexvix® Photosensitizer prodrug that accumulates in malignant bladder tissue; metabolized to proto | PPIX | Phase 4 | Non-muscle-invasive Bladder Cancer | Dec 2028 |
| Biofrontera | BF-200 ALA (Ameluz®) 5-aminolevulinic acid (ALA) prodrug; converted to protoporphyrin IX (PPIX) for photodynami | PPIX | Phase 3 | Superficial Basal Cell Carcinoma; Locally Advanced Colorectal Carcinoma | Feb 2029 |
Superficial Basal Cell Carcinoma (1) Locally Advanced Colorectal Carcinoma (1) Non-muscle-invasive Bladder Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.